Clinical relevance of plasma prostaglandin f2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.

Aihara, Kensaku; Handa, Tomohiro; Oga, Toru; Watanabe, Kizuku; Tanizawa, Kiminobu; Ikezoe, Kohei; Taguchi, Yoshio; ... Narumiya, Shuh; Wells, Athol U; Mishima, Michiaki

Aihara, Kensaku ...(et al). Clinical relevance of plasma prostaglandin f2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.. PloS one 2013, 8(6): e66017.

ISSUE DATE:
2013-06-11

URL:
http://hdl.handle.net/2433/175816

RIGHT:
© 2013 Aihara et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Clinical Relevance of Plasma Prostaglandin F$_{2\alpha}$ Metabolite Concentrations in Patients with Idiopathic Pulmonary Fibrosis

Kensaku Aihara$^1$, Tomohiro Handa$^{1,2}$, Toru Oga$^3$, Kizuku Watanabe$^1$, Kiminobu Tanizawa$^1$, Kohei Ikezoe$^1$, Yoshio Taguchi$^4$, Hiroe Sato$^5$, Kazuo Chin$^3$, Sonoko Nagai$^6$, Shuh Narumiya$^7$, Athol U. Wells$^3$*$^8$, Michiaki Mishima$^1$

1 Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2 Department of Rehabilitation Medicine, Kyoto University Hospital, Kyoto, Japan, 3 Department of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, 4 Department of Respiratory Medicine, Tenri Hospital, Tenri, Japan, 5 National Heart and Lung Institute, Imperial College London, London, United Kingdom, 6 Kyoto Central Clinic/Clinical Research Center, Kyoto, Japan, 7 Department of Pharmacology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 8 Royal Brompton Hospital, London, United Kingdom

Abstract

**Background:** Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology with few current treatment options. Recently, we determined an important role of prostaglandin F$_{2\alpha}$ (PGF$_{2\alpha}$) in pulmonary fibrosis by using a bleomycin-induced pulmonary fibrosis model and found an abundance of PGF$_{2\alpha}$ in bronchoalveolar lavage fluid of IPF patients. We investigated the role of PGF$_{2\alpha}$ in human IPF by assessing plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$, a stable metabolite of PGF$_{2\alpha}$.

**Methods:** We measured plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$ in 91 IPF patients and compared these values with those of controls (n = 25). We further investigated the relationships of plasma 15-keto-dihydro PGF$_{2\alpha}$ concentrations with disease severity and mortality.

**Results:** Plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$ were significantly higher in IPF patients than controls (p < 0.001). Plasma concentrations of this metabolite were significantly correlated with forced expiratory volume in 1 second ($R_s$ [correlation coefficient] = −0.34, p = 0.004), forced vital capacity ($R_s$ = −0.33, p = 0.005), diffusing capacity for carbon monoxide ($R_s$ = −0.36, p = 0.003), the composite physiologic index ($R_s$ = 0.40, p = 0.001), 6-minute walk distance ($R_s$ = −0.24, p = 0.04) and end-exercise oxygen saturation ($R_s$ = −0.25, p = 0.04) when patients with emphysema were excluded. Multivariate analysis using stepwise Cox proportional hazards model showed that a higher composite physiologic index (relative risk = 1.049, p = 0.002) and plasma 15-keto-dihydro PGF$_{2\alpha}$ concentrations (relative risk = 1.005, p = 0.002) were independently associated with an increased risk of mortality.

**Conclusions:** We demonstrated significant associations of plasma concentrations of PGF$_{2\alpha}$ metabolites with disease severity and prognosis, which support a potential pathogenic role for PGF$_{2\alpha}$ in human IPF.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible and usually lethal lung disease of unknown etiology that has limited therapeutic options [1]. Although IPF carries an overall poor prognosis [2], the clinical course of individual patients varies from slow progression to acute decompensation and death [3,4]. A variety of pathways and mechanisms underlying pulmonary fibrosis have been identified [5], but have not been well evaluated in the clinical arena.

Prostaglandins (PGs) are oxygenated metabolites of arachidonic acid produced by sequential catalysis of cyclooxygenase (COX) and respective synthase, and they contribute to a variety of physiological responses and pathological processes [6]. PGE$_2$ and PGA$_2$ are considered to exert antifibrotic effects [7]. However, we recently reported that PGF$_{2\alpha}$ facilitates pulmonary fibrosis through PGF receptor (FP) in a murine bleomycin-induced pulmonary fibrosis model [8]. In addition, PGF$_{2\alpha}$ is abundant in bronchoalveolar lavage fluid of human subjects with IPF, and stimulates proliferation and collagen production of lung fibroblasts.
via FP [8]. This indicates that PGF$_{2\alpha}$ produced in the lung of IPF patients may contribute to disease progression.

Endogenous PGF$_{2\alpha}$ is swiftly degraded in various organs including the lung to 13,14-dihydro-15-keto PGF$_{2\alpha}$ (15-keto-dihydro PGF$_{2\alpha}$, a stable metabolite of PGF$_{2\alpha}$, which has a longer half-life in the circulation and has been used as a reliable indicator of in vivo PGF$_{2\alpha}$ biosynthesis [9]. In the current study, we measured plasma concentrations of this metabolite in a cohort of IPF patients to clarify their clinical relevance and prognostic value.

Methods

Ethics Statement

This study was approved by Kyoto University Graduate School and Faculty of Medicine Ethics Committee and the Ethics Committee of Tenri Hospital, and written informed consent was obtained from all patients.

Study Subjects

The study population consisted of 91 IPF patients who visited Kyoto University Hospital from February 2008 through August 2011, and those who visited Tenri Hospital from April 2006 through September 2008. At the time of study entry, all of study patients had not been receiving any specific treatment for IPF. IPF was diagnosed on the basis of the current official joint statement on IPF [10]. In 28 patients, usual interstitial pneumonia was confirmed by surgical lung biopsy. Quantification of disease severity by pulmonary function tests [11], and suitability of prognostic indicators [12] may be confounded by coexistent emphysema in patients with IPF. Therefore we also performed a subgroup analysis of patients without emphysema. Emphysema on high-resolution computed tomography was defined as the presence of well-demarcated areas of decreased attenuation in comparison with contiguous normal lung, and delimited by a very thin (<1 mm) or no wall, with upper zone predominance [13]. Age- and body mass index-matched subjects without lung disease (n = 25) were recruited as controls.

Physiological Assessments

Pulmonary function tests were performed using CHESTAC system (Chest M.I. Inc., Tokyo, Japan). Diffusing capacity for carbon monoxide (DL$_{CO}$) was measured using the single-breath technique. Percent-predicted values were used for analyses. The composite physiologic index (CPI) was calculated as previously described [11]. Arterial blood gas analysis, including arterial partial pressure of oxygen (PaO$_2$) and arterial partial pressure of carbon dioxide (PaCO$_2$), was performed while patients were breathing room air at rest in the supine position. The alveolararterial oxygen pressure difference (A-aDO$_2$) was calculated according to a standard formula, using the respiratory exchange ratio of 0.8. Six-minute walk testing (6MWT) was performed as recommended by American Thoracic Society guidelines [14] and oxygen saturation was continuously monitored during 6MWT using a pulse oximeter (Pulsoc-300H, Konica Minolta Inc., Osaka, Japan).

Blood Sample Collection and Laboratory Assessments

Samples of peripheral venous blood were collected in the morning before breakfast. Plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$ were measured using an enzyme immunoassay kit (13,14-dihydro-15-keto Prostaglandin F$_{2\alpha}$ Ela kit; Cayman Chemical; Ann Arbor, MI, USA). Serum KL-6 levels were measured by a sandwich-type electrochemiluminescence immunoassay kit (Picolumi KL-6; Sanko Junyaku, Tokyo, Japan) and serum SP-D levels were measured by a sandwich-type enzyme immunoassay kit (SP-D kit Yamasa Ela H; Yamasa Shoyu, Chiba, Japan).

Doppler Echocardiography

Twenty-eight IPF patients recruited in Kyoto University Hospital underwent Doppler echocardiography at study entry. Doppler echocardiography was performed using conventional clinical echocardiographic equipment (Xario XG, Toshiba Medical Systems Co., Ltd, Tochigi, Japan): Systolic pulmonary arterial pressure (sPAP) at rest was calculated by the sum of estimated right atrial pressure and the transatrial gradient as previously reported [15]. Pulmonary hypertension (PH) was defined as sPAP of greater than or equal to 40 mmHg at rest [15].

Statistics

All statistical analyses were performed using JMP version 9 (SAS Institute, Cary, NC, USA). Continuous variables are expressed as mean±standard deviation. Comparisons of categorical data between two groups were performed by Fisher’s exact probability tests. Continuous variables were compared with the unpaired t-test if normally distributed, and the Mann-Whitney U test when the distribution was not normal. Correlations between pairs of variables were analyzed by Spearman’s rank correlation tests. For survival analysis, patients receiving lung transplantation during follow-up (n = 1) or subjects lost to follow-up (n = 10) were censored, and then the duration from entry to death, the transplant date, or the last visit was recorded. Mortality was first assessed for all risk factors using univariate Cox proportional hazard analysis, and then stepwise multivariate Cox proportional hazard analysis was performed to examine the prognostic predictive value of plasma 15-keto-dihydro PGF$_{2\alpha}$ concentrations while adjusting for other clinical predictors of cumulative mortality. Results of the regression analysis were presented in terms of relative risks (RRs) with corresponding 95% confidence intervals. Survival curves were obtained using the Kaplan-Meier method and the difference in survival rates between subgroups was calculated using a log-rank test. A p value less than 0.05 was considered to indicate statistical significance.

Results

Plasma 15-keto-dihydro PGF$_{2\alpha}$ Concentrations Correlate with Disease Severity Indices

The clinical characteristics of patients and controls are summarised in Table 1 (see Table S1 for the patient characteristics in each hospital). The proportions of females (p = 0.03) and never smokers (p<0.001) were significantly lower in IPF patients than those in control subjects. Among all 91 patients, 16 had concurrent emphysema. Plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$ were significantly higher in IPF patients than those in control subjects, regardless of the presence of concurrent emphysema (Figure 1, p<0.001).

To assess the clinical relevance of plasma 15-keto-dihydro PGF$_{2\alpha}$ concentrations, we investigated their relationships with disease duration, pulmonary function, arterial blood gas data and 6MWT data (Table 2). Spearman’s rank correlation analysis showed that plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$ were significantly correlated with forced expiratory volume in 1 second (FEV$_1$) (Rs [correlation coefficient] = −0.22, p = 0.03) but not with disease duration or other indices of disease severity. However, among patients without emphysema (n = 75), plasma concentrations of 15-keto-dihydro PGF$_{2\alpha}$ were significantly correlated with FEV$_1$ (Rs = −0.34, p = 0.004), forced vital capacity
Plasma PGF2α Metabolite in IPF

Plasma 15-keto-dihydro PGF2α Concentrations Predict Mortality

During a mean follow-up period of 29.8 (range: 0.5–74.9) months, 22 of 91 patients died. The major cause of death was respiratory failure due to the progression of IPF (n = 15), 4 patients died of lung cancer and 5 patients died suddenly at home from an unknown cause. Although none of the patients received IPF-specific treatment at entry, some underwent treatment with pirfenidone (n = 13), prednisone (n = 25), cyclophosphamide (n = 3), azathioprine (n = 4) and cyclosporine (n = 6) during a follow-up period. Combination therapy with two or more medications was used in 14 patients.

We assessed the relationships between clinical measurements and mortality using Cox proportional hazard model (Table 3). Among overall patients (n = 91) as well as patients without emphysema (n = 75), low FEV1, low FVC, low DLCO, high CPI, short 6-minute walk distance and low end-exercise oxygen saturation were significantly associated with an increased risk of mortality. Plasma concentrations of 15-keto-dihydro PGF2α were significantly associated with mortality (RR = 1.005, p<0.001), but sex, age and serum levels of KL-6 and SP-D were not. Multivariate analysis was performed using stepwise Cox proportional hazard model in which all significant predictors of mortality in univariate analyses were included as covariates. We found that high CPI (RR = 1.049, p = 0.002 in all patients; RR = 1.043, p = 0.016 in patients without emphysema) and increased plasma concentrations of 15-keto-dihydro PGF2α (RR = 1.005, p = 0.002

Figure 1. Comparison of plasma 15-keto-dihydro prostaglandin F2α concentrations in patients and controls. Horizontal bars indicate mean values. There were significant differences in plasma 15-keto-dihydro prostaglandin F2α concentrations between IPF patients with emphysema (n = 16) and controls (n = 25), and IPF patients without emphysema (n = 75) and controls. However, there was no difference in plasma 15-keto-dihydro prostaglandin F2α concentrations between IPF patients with emphysema and those without emphysema. doi:10.1371/journal.pone.0066017.g001

Table 1. Characteristics of patients and controls.

|                           | All patients (n = 91) | Emphysema excluded (n = 75) | Controls (n = 25) | p value* |
|---------------------------|-----------------------|-----------------------------|-------------------|----------|
| Sex, male/female          | 69/22                 | 57/18                       | 13/12             | 0.03     |
| Age, years                | 66.5 ± 7.9            | 66.0 ± 7.8                  | 64.6 ± 6.4        | 0.27     |
| BMI, kg/m²                | 23.4 ± 3.0            | 23.4 ± 3.0                  | 23.2 ± 2.2        | 0.80     |
| Nonsmokers                | 15                    | 14                          | 16                | <0.001   |
| Disease duration**, months | 16.0 ± 25.5           | 16.3 ± 25.4                 | NA                |          |
| FEV1, % predicted         | 98.6 ± 21.0           | 98.5 ± 21.6                 | NA                |          |
| FVC, % predicted          | 89.2 ± 22.1           | 87.6 ± 20.9                 | NA                |          |
| DLCO, % predicted         | 52.6 ± 17.7           | 52.1 ± 16.5                 | NA                |          |
| Composite physiologic index | 43.8 ± 14.0          | 43.7 ± 13.9                 | NA                |          |
| PaCO2, kPa                | 5.7 ± 0.9             | 5.7 ± 0.8                   | NA                |          |
| PaO2, kPa                 | 10.9 ± 1.7            | 11.3 ± 1.6                  | NA                |          |
| A-aDO2, kPa               | 1.4 ± 1.9             | 1.2 ± 1.7                   | NA                |          |
| Six-minute walk distance, m | 449.1 ± 92.0          | 454.9 ± 87.2                | NA                |          |
| End-exercise oxygen saturation, % | 87.9 ± 6.9 | 88.7 ± 6.4 | NA |          |
| Serum KL-6, U/mL          | 1135 ± 842            | 1112 ± 829                  | NA                |          |
| Serum SP-D, ng/mL         | 253 ± 211             | 263 ± 199                   | NA                |          |
| Plasma 15-keto-dihydro PGF2α, pg/mL | 193 ± 133 | 194 ± 140 | 37 ± 19 | <0.001 |

Data are presented as mean ± standard deviation.
*Comparison between all patients and controls.
**Time from diagnosis to blood sample collection.
BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; A-aDO2, alveolar-arterial oxygen pressure difference; SP-D, surfactant protein-D; PGF2α, prostaglandin F2α, NA, not available.
doi:10.1371/journal.pone.0066017.t001
Figure 2. Correlations of plasma 15-keto-dihydro prostaglandin F$_{2\alpha}$ concentrations with indices of disease severity. Scatter diagrams show the correlations of plasma 15-keto-dihydro prostaglandin F$_{2\alpha}$ concentrations with FVC (a), DL$_{CO}$ (b), six-minute walk distance (c) and end-exercise oxygen saturation (d) in IPF patients without emphysema. The $R_s$ value indicates the correlation coefficient. doi:10.1371/journal.pone.0066017.g002

Table 2. Relationships between plasma 15-keto-dihydro prostaglandin F$_{2\alpha}$ concentrations and clinical parameters in patients with idiopathic pulmonary fibrosis.

|                              | All patients (n = 91) |                     | Emphysema excluded (n = 75) |                     |
|------------------------------|-----------------------|---------------------|-----------------------------|---------------------|
|                              | Correlation coefficient | $p$ value           | Correlation coefficient     | $p$ value           |
| Disease duration*, months    | $-0.04$               | $0.20$              | $0.03$                      | $0.80$              |
| Pulmonary function           |                       |                     |                             |                     |
| FEV$_1$, % predicted         | $-0.22$               | $0.03$              | $-0.34$                     | $0.004$             |
| FVC, % predicted             | $-0.11$               | $0.28$              | $-0.33$                     | $0.005$             |
| DL$_{CO}$, % predicted       | $-0.16$               | $0.13$              | $-0.36$                     | $0.003$             |
| Composite physiologic index  | $0.19$                | $0.08$              | $0.40$                      | $0.001$             |
| Arterial blood gas data      |                       |                     |                             |                     |
| PaCO$_2$, kPa                | $-0.09$               | $0.40$              | $-0.13$                     | $0.30$              |
| PaO$_2$, kPa                 | $-0.14$               | $0.22$              | $-0.24$                     | $0.05$              |
| A-aDO$_2$, kPa               | $0.21$                | $0.06$              | $0.39$                      | $0.002$             |
| Six-minute walk test         |                       |                     |                             |                     |
| Six-minute walk distance, m  | $-0.21$               | $0.06$              | $-0.24$                     | $0.04$              |
| End-exercise oxygen saturation, % | $-0.14$   | $0.20$              | $-0.25$                     | $0.04$              |

*Time from diagnosis to blood sample collection.  
FEV$_1$, forced expiratory volume in 1 second; FVC, forced vital capacity; DL$_{CO}$, diffusing capacity for carbon monoxide; PaCO$_2$, arterial partial pressure of carbon dioxide; PaO$_2$, arterial partial pressure of oxygen; A-aDO$_2$, alveolar-arterial oxygen pressure difference.

doi:10.1371/journal.pone.0066017.t002
in all patients; RR = 1.005, *p* = 0.003 in patients without emphysema) were the independent predictors of mortality. The independent association of plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations with mortality was reproducibly found in each cohort (see Table S2).

Figure S1 shows the Kaplan-Meier survival curves when patients were divided into two groups, with plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations above or below the median value (156 pg/mL), respectively. Patients with higher plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations (≥156 pg/mL) had a significantly worse prognosis than patients with lower concentrations (*p* = 0.04).

**Plasma 15-keto-dihydro PGF\(_{2\alpha}\) Concentrations Are Associated with the Presence of Pulmonary Hypertension Assessed by Doppler Echocardiography**

Finally, since PH is a significant comorbidity which can affect prognosis in patients with IPF [16,17], we compared plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations according to the presence or absence of PH. Among patients with successful sPAP measurements, 8 of 28 had sPAP≥40 mmHg, which fulfilled the definition of PH. Plasma concentrations of 15-keto-dihydro PGF\(_{2\alpha}\) were significantly higher in patients with PH than in those without PH (317±291 pg/mL vs 172±75 pg/mL, *p* = 0.04). However, there were no significant differences in serum levels of KL-6 and SP-D between patients with and without PH (1503±444 U/mL vs 1252±735 U/mL, *p* = 0.38; and 367±181 ng/mL vs 347±314 ng/mL, *p* = 0.87, respectively).

**Discussion**

We demonstrated raised concentrations of 15-keto-dihydro PGF\(_{2\alpha}\), a stable metabolite of PGF\(_{2\alpha}\), in the plasma of patients with IPF. Plasma concentrations of this metabolite were significantly correlated with indices of disease severity including FEV\(_1\), FVC, DL\(_{CO}\), CPI, 6-minute walk distance and end-exercise oxygen saturation, when patients with emphysema were excluded. Furthermore, in our cohort of patients, higher plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations were significantly associated with an increased risk of mortality after adjusting for disease severity indices represented by CPI. Among patients with successful echocardiographic measurements, plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations were significantly higher in patients with PH than in those without PH.

Considering that IPF is a devastating lung disease with poor prognosis but highly variable clinical course, predicting which paths individual patients will take remains a central challenge for clinicians [18]. A primary finding of the present study was that plasma concentrations of PGF\(_{2\alpha}\) metabolite were significantly correlated with the severity of IPF as well as mortality. However, the relationships of plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations with pulmonary function, arterial blood gas data and 6MWT data differed according to the presence of concomitant emphysema, suggesting that emphysema is a significant confounding comorbidity in IPF. FVC, DL\(_{CO}\), CPI and desaturation during 6MWT predicted mortality in our cohort of patients with IPF, which is consistent with previous studies [11,17,19,20]. However, even after adjusting for these physiologic predictors, plasma 15-keto-dihydro PGF\(_{2\alpha}\) concentrations were significantly associated with mortality. We have recently shown by both *in vivo* and *in vitro* approaches that PGF\(_{2\alpha}\)-FP signaling mediates pulmonary fibrosis independently of transforming growth factor-β signaling [8], which is a well-known crucial pathway for fibrogenesis [21]. Raised concentrations of plasma PGF\(_{2\alpha}\) metabolite may reflect an upregulation of PGF\(_{2\alpha}\)-FP signaling pathway and subsequent fibrotic processes, which cannot be evaluated by a single measurement of pulmonary function or 6MWT. Indeed, the relationships between plasma concentration of PGF\(_{2\alpha}\) metabolite and physiological parameters of IPF tended to be significant but relatively weak.
Another possible explanation why plasma PGF\(_{2\alpha}\) metabolite concentrations predicted mortality was the impact of comorbid PH. In subgroup analysis, plasma PGF\(_{2\alpha}\) metabolite concentrations were significantly higher in patients with PH, whereas serum levels of KL-6 and SP-D did not differ between the subgroups. Since PH commonly complicates the course of IPF and potentially affects prognosis [16,17], the significant relationship of plasma levels of KL-6 and SP-D did not differ between the subgroups.

Since PGF\(_{2\alpha}\) is a locally bioactive hormone that is uncovered virtually in all tissues including lung [9], the source of PGF\(_{2\alpha}\) or its metabolite in the plasma of pulmonary fibrosis patients is speculative. For example, macrophages activated by proinflammatory stimuli produce PGF\(_{2\alpha}\) in large amounts [22]. PGF\(_{2\alpha}\) is also produced by type II alveolar epithelial cells [23], and widely upregulated COX-2 expression was observed in metaplastic epithelium in pulmonary fibrous disorders [24]. In addition, PGF synthase exists in contractile interstitial cells of bovine lungs, which are considered to be a precursor of myofibroblasts, main contributing cell types to fibrogenesis [25]. Thus, increased epithelial permeability in the lung of IPF patients [26] may allow PGF\(_{2\alpha}\) produced in the lungs to leak into the circulation, where it is instantly bioconverted through metabolism [9].

Another possible mechanism might be functional alteration in pulmonary arterial endothelium and/or smooth muscle cells, both of which play significant roles in the pathogenesis of pulmonary arterial hypertension [27]. Recent studies suggested that the pathogenesis of PH in IPF is a complicated interaction of epithelial cells, fibroblasts and vascular cells mediated by multiple factors including several growth factors [28], which can stimulate the expression of COX-2, thereby leading to the production of PGs [29]. The COX-2 pathway might be upregulated in pulmonary arterial endothelium and/or smooth muscle cells through hypoxic stimulus and/or the development of PH. This pathogenesis is worthy to be studied further because, in contrast, previously identified biomarkers of IPF, KL-6 and SP-D, were found to be mainly produced by alveolar epithelial cells [30,31].

Cytosolic phospholipase \(A_2\) (cPLA\(_2\)), which cleaves phospholipids and yields arachidonic acids including PGs as well as lysophospholipids, might play a pivotal role in the pathogenesis of pulmonary fibrosis [32]. Thus, PGF\(_{2\alpha}\) and lysophosphatidic acids, both derived from the breakdown of phospholipids by cPLA\(_2\) and possible stimulators of fibrosis [8,33], might act complementarily to affect the progression of disease.

The present study has some limitations. Firstly, this is a relatively small cohort study with IPF patients alone. Since PGF\(_{2\alpha}\) is produced by various cells and is implicated in the regulation of intricate pathophysiological processes [9], further studies on the utility of plasma 15-keto-dihydro PGF\(_{2\alpha}\), in patients with systemic diseases associated with interstitial lung disease are warranted. At the time of blood sampling, all study participants were not receiving any specific treatment for IPF. Hence the possible effects of IPF-specific medication on the value and usefulness of plasma 15-keto-dihydro PGF\(_{2\alpha}\) should also be assessed for future clinical use. Second, since the presence and degree of PH were not evaluated by right heart catheterisation and echocardiographic data were not available in all patients, our current findings should be interpreted with caution and further studies are necessary.

In summary, we demonstrated significant associations of plasma concentrations of PGF\(_{2\alpha}\) metabolites with disease severity and prognosis in IPF patients. Although further larger studies are needed to confirm the clinical utility of this metabolite, the current findings support a potential pathogenic role for PGF\(_{2\alpha}\) in human IPF. Our current results also provide a more integrated understanding of this devastating and complex disease and may help in the development of new antifibrotic drugs.

Supporting Information

Figure S1 Kaplan-Meier survival analysis grouped by baseline plasma 15-keto-dihydro prostaglandin F\(_{2\alpha}\) concentrations. The \(\text{black line}\) represents the group of IPF patients with baseline plasma 15-keto-dihydro prostaglandin F\(_{2\alpha}\) concentrations greater than or equal to 156 pg/mL. The \(\text{gray line}\) represents the group of IPF patients with baseline plasma 15-keto-dihydro prostaglandin F\(_{2\alpha}\) concentrations less than 156 pg/mL. (TIF)

Table S1 Patient characteristics of two cohorts. (DOC)

Table S2 Cox proportional hazard model results for evaluating the risk of mortality. (DOC)

Author Contributions

Conceived and designed the experiments: KA TH TO HS S. Narumiya AUW. Performed the experiments: KA TH KW KT KI YT KC S. Nagai MM. Wrote the paper: KA TH TO HS S. Narumiya AUW.

References

1. King TE, Jr. Parado A, Selman M (2011) Idiopathic pulmonary fibrosis. Lancet 378: 1949–1961.
2. Ley B, Collard HR, King TE, Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183: 431–440.
3. Martinez FJ, Safin S, Weycker D, Starke RM, Bradford WZ, et al. (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Am Intern Med 142: 963–967.
4. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, et al. (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137: 129–137.
5. Wynn TA (2011) Integrating mechanisms of pulmonary fibrosis. J Exp Med 208: 1339–1350.
6. Hirata T, Narumiya S (2011) Prostanoid receptors. Chem Rev 111: 6209–6230.
7. Huang SK, Perez-Gruisena M (2006) Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time? Chest 133: 1442–1450.
8. Ota T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, et al. (2009) Prostaglandin F2alpha receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 15: 1426–1430.
9. Rau S (2007) Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med Res Rev 27: 135–460.
10. Raghu G, Gollard HR, Egan JJ, Martinez FJ, Behr J, et al. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788–824.
11. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, et al. (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167: 962–969.
12. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, et al. (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38: 176–183.
13. Hanwell DM, Bankier AA, MacMahon H, McLaughlin P, Muller NL, et al. (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246: 697–722.
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111–117.
15. Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, et al. (2006) Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129: 1246–1252.
16. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129: 746–752.
17. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, et al. (2007) Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131: 650–656.
18. Ley B, Gollard HR (2012) Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185: 6–7.
19. King TE Jr, Tsevat J, Brown KR, Cherniack RM (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164: 1171–1181.
20. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, et al. (2006) Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 174: 803–809.
21. Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286–1292.
22. Hsueh W (1979) Prostaglandin biosynthesis in pulmonary macrophages. Am J Pathol 97: 137–148.
23. Taylor L, Polgar P, McAteer JA, Douglas WH (1979) Prostaglandin production by type II alveolar epithelial cells. Biochim Biophys Acta 572: 502–509.
24. Lappe-Blanco E, Kaarteenaho-Wiik R, Maasila PK, Anttila S, Paakkko P, et al. (2006) COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol 126: 717–724.
25. Fukui M, Fujimoto T, Watanabe K, Endo K, Kuno K (1996) Prosta glandin F synthase is localized to contractile interstitial cells in bovine lung. J Histochem Cytochem 44: 251–257.
26. Mogulkoc N, Brutsche MH, Bishop PW, Murby B, Greaves MS, et al. (2001) Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 56: 916–923.
27. Archer SL, Weir EK, Wilkins MR (2010) Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121: 2043–2066.
28. Farkas L, Gaudel J, Voelkel NF, Kolb M (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 45: 1–15.
29. Tanabe T, Tohmai N (2002) Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 66–69: 95–114.
30. Kohno N, Kyoizumi S, Awaya Y, Fukuzara H, Yamakido M, et al. (1989) New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 96: 68–73.
31. Mason RJ, Greene K, Voelker DR (1998) Surfactant protein A and surfactant protein D in health and disease. Am J Physiol 275: L1–L13.
32. Nagase T, Usami N, Ishii S, Kita Y, Yamamoto H, et al. (2002) A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med 8: 480–484.
33. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, et al. (2008) The lyso phosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14: 45–54.